SILVER SPRING, Maryland & RESEARCH TRIANGLE PARK, North Carolina, July 2, 2026
United Therapeutics Corporation has announced the acquisition of Thymmune Therapeutics, a privately held preclinical biotechnology company developing regenerative thymic cell therapies designed to restore immune function and improve transplant outcomes. The acquisition strengthens United Therapeutics’ regenerative medicine and organ transplantation portfolio, expanding its capabilities in immunomodulatory therapies, stem cell technologies, and organ replacement innovation. Under the terms of the agreement, United Therapeutics will acquire Thymmune for $140 million in cash, subject to post-closing adjustments, with the potential for an additional $160 million in milestone-based earn-out payments tied to future clinical and regulatory achievements through 2031. The strategic transaction reflects United Therapeutics’ long-term commitment to advancing cell-based regenerative therapies that address severe immune disorders while supporting its broader mission of increasing the availability and long-term success of transplantable organs through innovative biotechnology.
Thymic Cell Therapy Platform Expands Regenerative Medicine Pipeline
The acquisition brings Thymmune Therapeutics’ proprietary induced pluripotent stem cell (iPSC)-based thymic cell platform into United Therapeutics’ expanding regenerative medicine portfolio. The company’s technology converts human induced pluripotent stem cells into functional thymic cells, which mature within the body to restore healthy T-cell development and improve immune system function. The thymus plays a critical role in educating T-cells that protect the body against infections, cancer, and autoimmune diseases, making thymic regeneration a promising therapeutic strategy for numerous immune-related disorders.
Thymmune’s lead investigational therapy, THY-100, is currently in preclinical development for congenital athymia, a rare and life-threatening condition in which infants are born without a functioning thymus. Preclinical studies have demonstrated that THY-100 can stimulate the formation of a functional neo-thymus, enabling the generation of healthy T-cells and potentially restoring immune competence. The technology also holds future potential for applications in post-transplant immune tolerance, autoimmune diseases, immunodeficiencies, and age-related immune decline.
Acquisition Supports Organ Transplant Innovation
Advertisement
United Therapeutics believes the acquisition strategically complements its existing UThymoKidney™ clinical development program, which focuses on expanding the supply of transplantable organs through advanced regenerative technologies. By integrating Thymmune’s thymic regeneration platform, the company aims to develop therapies capable of improving immune tolerance following organ transplantation while reducing dependence on long-term immunosuppressive medications. Enhancing T-cell receptor diversity through regenerative thymic therapies may allow transplanted organs to be accepted more naturally by the immune system, improving long-term transplant outcomes and reducing complications associated with immune rejection.
Beyond transplantation, the platform could create entirely new therapeutic opportunities for treating severe immune-mediated disorders by addressing the underlying causes of immune dysfunction rather than simply managing symptoms. This scientific approach aligns closely with United Therapeutics’ long-term vision of combining regenerative medicine, organ bioengineering, and cell therapy to transform patient care.
Strategic Acquisition Reinforces Cell Therapy Leadership
The acquisition further establishes United Therapeutics as a leader in the rapidly evolving fields of regenerative medicine, cell therapy, and organ replacement technologies. By combining its expertise in rare diseases, organ manufacturing, and transplantation with Thymmune’s innovative thymic regeneration platform, the company is expanding its ability to develop next-generation therapies capable of restoring normal immune function across multiple serious diseases. The transaction also highlights increasing investment throughout the biotechnology industry in stem cell-derived regenerative therapies that address significant unmet medical needs through tissue restoration rather than conventional pharmaceutical intervention.
As clinical development progresses, THY-100 may represent one of the first regenerative thymic therapies designed to rebuild immune function and improve transplant tolerance, potentially opening new treatment pathways for patients with congenital immune disorders, autoimmune diseases, and transplant-related complications. The acquisition reflects United Therapeutics’ continued commitment to advancing transformative regenerative technologies that have the potential to reshape the future of transplantation, immune medicine, and precision cell therapy.
Source: United Therapeutics, Thymmune Therapeutics press release
